CoChat

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Open access
Alharbi, Saleh Hadi · 2024 · Therapeutic Advances in Endocrinology and Metabolism

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 78 of the 118 sources its claims cite were checked for support.

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic agents with potent anti-inflammatory properties and diverse clinical implications. This in-depth review article explores the mechanisms behind the anti-inflammatory actions of GLP-1RAs and assesses their prospective applicability in a wide range of disease scenarios. The current review establishes the significance of comprehending the anti-inflammatory role of GLP-1RAs and identifies pertinent research gaps. A concise overview of inflammation and its clinical consequences underscores the critical need for effective anti-inflammatory interventions. Subsequently, the article elucidates the intricate mechanisms through which GLP-1RAs modulate immune cell signaling and regulate the nuclear factor-kappa B (NF-κB) pathway. Detailed discussions encompass their impact on inflammatory responses, cytokine production, and attenuation of oxidative stress. The exposition is substantiated by a collection of pertinent examples and an extensive array of references from both preclinical and clinical investigations. The historical trajectory of GLP-1RA drugs, including exenatide, lixisenatide, liraglutide, and semaglutide, is traced to delineate their development as therapeutic agents. Moreover, the review emphasizes the therapeutic potential of GLP-1RAs in specific disease contexts like type 2 diabetes, a neurodegenerative disorder, and inflammatory bowel disease (IBD), shedding light on their anti-inflammatory effects through rigorous examination of preclinical and clinical studies. The article also provides an outlook on future perspectives for GLP-1RAs, encompassing the domains of diabetes, neurodegenerative diseases, and IBD. In conclusion, GLP-1RAs exhibit substantial anti-inflammatory effects, rendering them promising therapeutic agents with broad clinical implications. They are very useful in a wide variety of diseases because they regulate immunological responses, block NF-κB activation, and decrease production of pro-inflammatory cytokines. Ongoing research endeavors aim to optimize their therapeutic use, delineate patient-specific treatment paradigms, and explore novel therapeutic applications. GLP-1RAs represent a significant breakthrough in anti-inflammatory therapy, offering novel treatment options, and improved patient outcomes.

Overview

CoChat Summary

TL;DR

This review argues that GLP-1 receptor agonists (GLP-1RAs) have anti-inflammatory effects beyond glucose lowering, acting through immune-cell signaling, NF-κB suppression, oxidative stress reduction, and related pathways. It concludes that these drugs show promise across type 2 diabetes, neurodegenerative disease, and inflammatory bowel disease, but emphasizes that more long-term and disease-specific evidence is needed.

Key findings

  • The review identifies several anti-inflammatory mechanisms for GLP-1RAs: suppression of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β; increased IL-10; inhibition of NF-κB; activation of AMPK; and reduction of reactive oxygen species.
  • In diabetes-related studies, liraglutide and semaglutide improved glycemic outcomes and were also linked to inflammation reductions; for example, liraglutide reduced the mean CRP concentration in a retrospective study of obese individuals with T2DM, and semaglutide significantly reduced hs-CRP in people with T2D and cardiovascular disease.
  • In obesity/weight-loss trials cited in the review, liraglutide 3.0 mg in the SCALE study produced dose-responsive weight loss of 6.0 to 8.8 kg, versus 0.2 to 3.0 kg with placebo; in another trial, exenatide plus lifestyle change led to −6.2 ± 0.5 kg versus −4.0 ± 0.5 kg with lifestyle plus placebo.
  • For neurodegenerative disease, the review cites a preliminary clinical trial in Parkinson’s disease where exenatide improved patients by 2.7 points on the MDS-UPDRS after 12 months, compared with a 2.2-point decline in controls, and a pilot study in 45 individuals with mild PD using single-blind design.

Methods

  • Narrative review of preclinical and clinical literature on GLP-1RAs and inflammation, with disease-focused discussion spanning diabetes, neurodegenerative disorders, and inflammatory bowel disease.
  • The paper synthesizes examples from animal models, cell studies, retrospective studies, and clinical trials; specific cited studies include obese individuals with T2DM, AD and PD patients, and IBD models/patients.
  • Main analysis is qualitative/mechanistic: the review organizes evidence by pathways and disease contexts rather than performing a meta-analysis or pooled quantitative synthesis.

Limitations

  • The paper states that there is limited long-term data on the anti-inflammatory effects of GLP-1RAs across diseases and that these drugs have not yet been tested for long-term effectiveness and safety in terms of inflammation.
  • It also states that further studies are necessary to determine optimal dosage schedules, treatment periods, and the best combinations with other therapies.
  • Evident from the text: this is a review rather than an original study, so its conclusions depend on the quality and heterogeneity of the cited studies; the paper itself notes that responses may vary by disease severity, comorbidities, and patient characteristics.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/20420188231222367

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. A schematic representation of the mechanism of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) inducing anti-inflammatory response while treating obesity, neurodegenerative disorders, and IBD. The role of GLP-1RA in obesity, neurodegenerative and IBD disorders is accomplished by NFκB and PI3K-Akt pathways, leading to the anti-inflammatory effect, by downregulation the pro-inflammatory cytokines and chemokines like IL-6, IL-8, TNF-α, IL-21, and IFNγ. As a result of these pathways, various tissues are more anti-oxidative, which reduces obesity, neurodegenerative, and IBD complications. In neurodegenerative conditions, β-cells undergo differentiation which enhances their neuroprotective capabilities and lessens the extent of neuroinflammation. Akt, activating receptor tyrosine kinase; CXCL8, C-X-C motif chemokine ligand 8; DPP-4, dipeptidyl peptidase-4; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; GLP-1, Glucagon-like peptide-1; GLP-1RA, Glucagon-like peptide-1 receptor agonists; IBD, inflammatory bowel disease; IFN-γ, Interferon-γ; IL-8, interleukin-8; IL-6, interleukin-6; IL-21, interleukin-21; NFκB, Nuclear Factor-kappa B; PI3k, phosphoinositide-3-3kinase-protein kinase; Th1, T-helper-1; TNF-α, Tumor necrosis factor- α.
Figure 1. A schematic representation of the mechanism of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) inducing anti-inflammatory response while treating obesity, neurodegenerative disorders, and IBD. The role of GLP-1RA in obesity, neurodegenerative and IBD disorders is accomplished by NFκB and PI3K-Akt pathways, leading to the anti-inflammatory effect, by downregulation the pro-inflammatory cytokines and chemokines like IL-6, IL-8, TNF-α, IL-21, and IFNγ. As a result of these pathways, various tissues are more anti-oxidative, which reduces obesity, neurodegenerative, and IBD complications. In neurodegenerative conditions, β-cells undergo differentiation which enhances their neuroprotective capabilities and lessens the extent of neuroinflammation. Akt, activating receptor tyrosine kinase; CXCL8, C-X-C motif chemokine ligand 8; DPP-4, dipeptidyl peptidase-4; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; GLP-1, Glucagon-like peptide-1; GLP-1RA, Glucagon-like peptide-1 receptor agonists; IBD, inflammatory bowel disease; IFN-γ, Interferon-γ; IL-8, interleukin-8; IL-6, interleukin-6; IL-21, interleukin-21; NFκB, Nuclear Factor-kappa B; PI3k, phosphoinositide-3-3kinase-protein kinase; Th1, T-helper-1; TNF-α, Tumor necrosis factor- α.CC BY-NC · PubMed Central

Verification

Claims the paper makes

65 Valid · 10 Not valid · 35 Not checked · 26 Own results and interpretations

75 more claims · 38 with their cited sources checked

Create a free account to see all 136 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 47
  • Probably not a substantial claim. 13
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 116 references

Research works printed but not linked: 2

  1. Yang F, 2021, Front Pharmacol, 12, 1
  2. Lee Y-S, 2016, Mediators Inflamm, 11, 1

Cited by

See all 358

Metadata

Authors
Alharbi, S. H.
Affiliations
Imam Mohammad ibn Saud Islamic University (SA)
Corresponding author
Alharbi, Saleh Hadi
Venue
Therapeutic Advances in Endocrinology and Metabolism
Published
2024-01
Volume
15
Pages
20420188231222367-20420188231222367
ISSN
  • 2042-0188 (ISSN-L)
  • 2042-0196
OpenAlex
W4391294421
Cited by
358
References
116
Citations by year
2026: 169 · 2025: 147 · 2024: 42
FWCI
20.88
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Endocrinology and Metabolism (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
GLP-1 receptor agonists, anti-inflammatory activity, NF-κB signaling, inflammatory cytokines, oxidative stress, exenatide, lixisenatide, liraglutide, semaglutide, type 2 diabetes, neurodegenerative diseases, inflammatory bowel disease, immune cell signaling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. https://app.cochat.ai/papers/10.1177/20420188231222367
The paper
Alharbi, S. H. (2024). Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/20420188231222367

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.